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Introduction
Breast cancer (BC) is the most common type of cancer and the sec-
ond leading cause of cancer-related death in women worldwide. 
Despite increasing knowledge of BC biology and huge progress in 
early detection, approximately 30% of patients with early-stage 
BC experience disease recurrence (1). Development and progres-
sion of cancer are intimately regulated by an evolving crosstalk 
between tumor cells and surrounding stromal cells, which are 
composed of immune/inflammatory cells, endothelial cells, peri-
cytes, and cancer-associated fibroblasts (CAFs) (2).
CAFs comprise a very heterogeneous cell population derived 
from different cellular sources, including resident fibroblasts, 
bone marrow–derived progenitor cells, adult mesenchymal stem 
cells, epithelial and endothelial cells, pericytes, and preadipo-
cytes (3–5). Because of the heterogeneity of CAFs, there is no sin-
gle molecular marker defining those fibroblastic cells. The most 
common marker, α-smooth muscle actin (αSMA), is used to define 
the activated state of fibroblasts, also known as “myofibroblasts,” 
although recent data from fibrosis models suggest that αSMA is an 
inconsistent marker of activated fibroblasts (6). Other molecules 
such as fibroblast-activating protein (FAP), fibroblast-specific pro-
tein 1 (FSP1), platelet-derived growth factor receptors (PDGFRs), 
and neural/glial antigen 2 (NG2) are also considered as CAF mark-
ers, but they are neither exclusively specific for this cell type, nor 
expressed by all CAFs (7, 8). CAFs have been shown to contribute 
to most of the hallmarks of cancer (9). Classically, protumorigenic 
effects leading to increased tumor growth, invasion, and metasta-
sis are assigned to CAFs. Those direct or indirect effects are relat-
ed, at least, to their capacity to produce growth factors (5), to pro-
mote angiogenesis (10), inflammation (11), and immune response 
(12), to regulate metabolic reprogramming (13), and to contribute 
to the remodeling and mechanotransduction of the extracellu-
lar matrix (ECM) (14). Although there is mounting evidence that 
CAFs are good targets for new anticancer therapies (5, 15), recent 
studies reported tumor-inhibitory effects of CAFs on tumor pro-
gression. Indeed, the genetic depletion of αSMA+ CAFs in preclin-
ical models of pancreatic cancer led, surprisingly, to increased 
tumor growth rather than to an expected reduced cancer progres-
sion (16, 17). Altogether, these data highlight CAF heterogeneity, 
not only in terms of cellular sources and biomarkers, but also in 
their capacity to promote or inhibit tumor progression. Identify-
ing molecular determinants of functionally distinct CAF subsets is 
therefore critical to elucidate the contrasting biological actions of 
these stromal cells during cancer progression.
Tumor- and stroma-derived PDGFs (PDGF-AA, PDGF-BB, 
PDGF-AB, PDGF-CC, and PDGF-DD) signal by binding to their 
tyrosine kinase receptors (PDGFRα and PDGFRβ) and play a 
key role in the recruitment and phenotypic features of CAFs that 
infiltrate BCs (18–20). PDGFs initiate the desmoplastic reaction, 
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a collagen-binding mesenchymal integrin, emerged as a novel 
CAF marker (27). The expression of this integrin is correlated with 
myofibroblast differentiation, matrix reorganization, and collagen 
deposition (28–30). While integrin α11 function in wound healing 
has been well described (31), only a very limited number of reports 
have assessed its role in cancer. In lung cancer, stromal integrin 
α11 has been reported to increase the tumorigenicity of cancer 
cells by regulating IGF-2 production (32) and matrix stiffness (33). 
stimulate angiogenesis, and promote tumor growth and metastat-
ic dissemination (21). PDGF signaling in CAFs has been shown to 
act as a determinant of the molecular subtype in BC (18). Previous 
studies have also reported that PDGFRβ expression in fibroblasts 
of BC patients is associated with aggressiveness, poor progno-
sis, and altered therapeutic response (22, 23). PDGFRβ signaling 
is regulated not only by growth factors but also by a functional 
interplay with integrins (24–26). Recently, integrin α11 (ITGA11), 
Figure 1. High integrin α11 expression associates with tumor progression in PyMT mouse breast tumor model. PyMT breast tumors analyzed at different 
stages: hyperplasia, adenoma, early carcinoma, and late carcinoma (5, 7, 10, and 14 weeks, respectively). (A) Quantitative reverse transcriptase PCR of 
Itga11 mRNA levels. Median of 5–6 tumors normalized to TBP. One-way ANOVA with Holm-Šidák multiple-comparisons test. (B) Western blot of ITGA11 
protein levels. Median of 3 tumors normalized to HSC-70. One-way ANOVA with Holm-Šidák multiple-comparisons test. (C) Kaplan-Meier plot showing 
the appearance of palpable tumors in PyMT Itga11+/+ (WT) (n = 19) and Itga11–/– (KO) mice (n = 19). Log-rank (Mantel-Cox) test. (D) Tumor growth kinetics (n 
= 19 WT, n = 19 KO mice, 2 tumors per mouse). Two-way ANOVA test with Holm-Šidák multiple-comparisons test. (E) Tumor mass at 14 weeks. Median of 
tumor mass (n = 38 WT, n = 30 KO tumors). Mann-Whitney test. (F) Representative pictures of tumors at sacrifice. (G) Kaplan-Meier plot showing tumor 
growth delay in KO mice. Data are presented as the percentage of WT (n = 19) and KO (n = 29) mice reaching 1000 mm3 of tumor volume. Log-rank (Man-
tel-Cox) test. (H) Representative images of H&E staining of tumors. Scale bars: 2 mm (original); 0.5 mm (zoom). ***P < 0.001.
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PyMT tumors were characterized by large and dense tumor lob-
ules with high collagen content (Figure 1H and Supplemental 
Figure 1, A and B; supplemental material available online with 
this article; https://doi.org/10.1172/JCI125890DS1). In contrast, 
KO PyMT tumors were composed of small lobules intermingled 
with adipose tissue and less collagen deposition (Figure 1H and 
Supplemental Figure 1, A and B). Strikingly, Itga11 deficiency 
dramatically reduced metastasis formation (Figure 2, A–C). At 
week 14, a twice-lower incidence of pulmonary metastases was 
seen in KO mice (40% of KO mice vs. 100% of WT mice) (Figure 
2B). Importantly, such defect in lung metastasis incidence was 
still pronounced at later time points (KO late group: >14 weeks) 
when tumors reached a volume of 1000 mm3 (Figure 2, B and C). 
Note that only KO and KO late mice with metastasis (5 of 12 and 
4 of 8 mice, respectively) were taken into account for metastatic 
index determination (Figure 2C).
Integrin α11 defines a subset of PDGFRβ+ CAFs. Immunohis-
tochemical (IHC) stainings were conducted on primary PyMT 
tumors at different stages (Figure 3A). Anti-α11 antibody speci-
ficity was assessed using Itga11-deficient PyMT tumors (Figure 
3A). Integrin α11 positivity was easily detected at week 10 and 
intense at week 14 (Figure 3A). As expected, integrin α11 staining 
was mostly restricted to the stromal compartment, confirmed also 
by the absence of association with pan-cytokeratin (Supplemen-
tal Figure 1C). Remarkably, integrin α11 strongly colocalized with 
PDGFRβ and was poorly associated with other stromal markers 
such as αSMA, PDGFRα, NG2 (Figure 3A), FAP, or FSP1 (Supple-
mental Figure 1D). Notably, PDGFRβ staining was concomitant-
ly detected in early tumors with NG2 (weeks 5 and 7), a pericyte 
marker (Figure 3A). A computerized quantification revealed that 
60% of total α11+ cells were positive for PDGFRβ, while a low 
proportion of these cells were also positive for another marker: 
PDGFRα (<9%), αSMA (<9%), FAP (<23%), FSP1 (<6%), or NG2 
(<12%) (Figure 3A and Supplemental Figure 1D). Thus, integrin α11 
is mainly expressed by PDGFRβ+ CAFs. Accordingly, higher lev-
els of PDGFRβ mRNAs (Figure 3B) and proteins (Figure 3C) were 
detected in PyMT tumors compared with hyperplastic tissues. In 
sharp contrast to its counterpart isoform, PDGFRα expression was 
The contribution of integrin α11 in BC progression and its cross-
talk with the surrounding tyrosine kinase receptors has not been 
yet documented. Prompted by findings of prominent integrin 
α11 expression in human BCs, we set out to identify the subset of 
CAFs expressing integrin α11, to investigate its contribution to BC 
growth and invasion in vitro and in vivo, and to molecularly define 
its role in CAF functions.
Results
Genetic Itga11 ablation in mice delays tumor growth and drastical-
ly reduces metastasis. We used the transgenic polyoma middle 
T oncogene–induced (PyMT-induced) mouse model (FVB/N 
genetic background), which accurately reproduces the stepwise 
progression of human BC with high metastatic dissemination to 
lungs (34). This model was also chosen for its high content of des-
moplasia and infiltrating stromal cells, particularly fibroblasts at 
all stages of tumor progression. We first assessed integrin α11 
expression, at both the mRNA and the protein level, at different 
time points of PyMT primary tumor development. A progressive 
increase of α11 expression was evidenced from hyperplastic nod-
ules (5 weeks) to carcinoma tumors (10–14 weeks) (Figure 1, A and 
B). Itga11-deficient mice (Itga11–/– FVB/N genetic background) 
were crossed with PyMT mice, resulting in 2 groups of female 
mice, hemizygous for PyMT transgene: PyMT Itga11+/+ (WT) and 
PyMT Itga11–/– (KO). Phenotypically, Itga11-deficient mice show 
dwarfism, increased mortality, and defective incisors (35) that 
were maintained in the generated PyMT Itga11-KO mice. Itga11 
genetic ablation led to a significant delay in the appearance of 
palpable tumors (Figure 1C) and reduction of tumor growth 
(Figure 1, D and E). The average time for tumor appearance in 
50% of mice was 8 weeks in WT mice and 12 weeks in KO mice 
(Figure 1C). Tumor volume at sacrifice (week 14) was reduced 
more than 5-fold (Figure 1, D–F) in KO PyMT mice compared 
with WT PyMT mice. A tumor growth delay of about 3 weeks was 
observed between the 2 genotypes when a group of KO PyMT 
mice was left for longer than 14 weeks (“KO late”), until tumors 
reached a volume of 1000 mm3 as observed in WT mice at 14 
weeks (Figure 1G). This group was monitored until week 18. WT 
Figure 2. High integrin α11 expression associates with metastasis. (A) Representative images of H&E staining of lungs issued from PyMT WT and KO mice. 
Scale bars: 1 mm (original); 250 μm (zoom). (B and C) Lung metastasis in mice at sacrifice (14 weeks for WT and KO groups and when tumors reached a 1000-
mm3 volume for the “KO late” group). Results are expressed as percentage of mice with lung metastasis (B) and median of metastatic index (lung tumor area/
total lung area) analyzed in mice bearing metastasis (C); n = 12 (WT); n = 5 (KO); n = 4 (KO late). One-way ANOVA with Dunn’s multiple-comparisons test.
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Figure 3. Integrin α11 defines a PDGFRβ+ CAF subpopulation, and its expression is increased during tumor progression. (A) Representative pictures of H&E 
and immunofluorescence staining of PyMT mice at different stages (left panel) and PyMT Itga11-WT and -KO mice at late stage (14 weeks) (right panel). 
Immunofluorescence confocal pictures show the costaining of integrin α11 (red) and αSMA, PDGFRα, or PDGFRβ (green). Nuclei stained with DAPI (blue). Scale 
bars: 50 μm. The percentages of cells positive for integrin α11 and a second marker compared with the total number of α11+ cells are indicated (“Colocalization”). 
Colocalization was determined by a computerized method on more than 12 stromal fields per tumor (n = 8 for each genotype). (B and C) Quantification of Pdgfrb 
mRNA levels (quantitative reverse transcriptase PCR, data normalized to TBP) (n = 6) (B) and protein levels (Western blot, data normalized to HSC-70) (n = 3) (C) 
in PyMT tumors. Representative pictures of Western blots are shown in the right panel. One-way ANOVA with Holm-Šidák multiple-comparisons test.
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cohorts using cBioPortal (TCGA breast and METABRIC) and the 
bc-GenExMiner genomic tool (36 data sets including 5861 BC 
patients). For each cohort (TCGA, METABRIC, and GenExMiner), 
genes with Pearson’s correlation coefficients greater than 0.5 were 
selected and intersected (Figure 5E and Supplemental Table 2) to 
produce a single list of coexpressed genes (n = 51) defined as the 
ITGA11-associated gene signature. Pathway enrichment analysis 
using the Reactome knowledgebase (37) revealed that pathways 
significantly (FDR Q value < 0.05) enriched in ITGA11-associated 
gene signature included at least extracellular matrix organization, 
collagen degradation, integrin cell surface interactions, and signaling 
by PDGF (Figure 5F and Supplemental Table 3).
To further characterize the cell subset expressing ITGA11 
in human BC, we correlated its mRNA expression levels with 12 
genes representative of different tumor-associated cell popula-
tions. In bc-GenExMiner analysis, ITGA11 mRNA levels poorly 
correlated with epithelial markers (E-cadherin/CDH1: Pearson’s 
r = 0.01), pericyte markers (chondroitin sulfate proteoglycan 
NG2/CSPG4: r = 0.16), and endothelial markers (PECAM1: r = 
0.04) (Figure 5G and Supplemental Figure 4D). In contrast, stron-
ger correlations were observed with several markers of activated 
fibroblasts, including αSMA (ACTA2: r = 0.41), PDGFRβ (PDG-
FRB: r = 0.47), FAP (r = 0.58), lysyl oxidase (LOX: r = 0.61), fibrillar 
collagens (COL1A1: r = 0.53; COL3A1: r = 0.45; COL5A1: r = 0.63), 
and collagen type X (COL10A1: r = 0.69). In line with the in vivo 
data, ITGA11 correlated with PDGFRB, but not with PDGFRA (r = 
0.28). Similar results were confirmed in TCGA breast and META-
BRIC cohorts. In addition, the TCSBN database (38) was used to 
analyze the integrative coexpression landscape of integrin α11 
with query genes (CDH1, ACTA2, CSPG4, PDGFRA, and PDG-
FRB) in normal and tumoral breast tissues (Supplemental Figure 
5). Again, a high ITGA11 coexpression with stromal markers was 
found in BC tissues compared with the normal ones. Among the 
neighbor genes of the ITGA11 cluster, we found many matrix-re-
lated proteins: collagens (COL3A1, COL4A2, COL6A3, COL10A1, 
COL11A1, and COL12A1), fibronectin (FN1), thrombospondin 
2 (THBS2), lumican (LUM), laminin A4 (LAMA4), and entactin 
(NID1), as well as functional proteins such as NOX4, PDGFRB, and 
LRP1 (Supplemental Figure 5).
Integrin α11/PDGFRβ density associates with a poor outcome in 
human BC. We next performed double immunostaining of inte-
grin α11 and PDGFRβ in human BC samples and the associated 
normal tissues of DCIS and IDC (n = 68 of different BC subtypes) 
(Figure 6A). Densities of integrin α11 or PDGFRβ were 2- to 3-fold 
higher in IDC tumors compared with DCIS (Figure 6, B–D). The 
increase in integrin α11 and PDGFRβ colocalization (percentage 
of positive cells per tumor area) was more pronounced in IDC ver-
sus DCIS (5-fold increase). This was particularly evident in more 
aggressive BC molecular subtypes (HER2 and TNBC). In line with 
the mouse study, more than 70% of α11+ CAFs were positive for 
PDGFRβ and more than 60% of PDGFRβ+ CAFs were positive for 
α11 in IDC tumors (Figure 6, E and F). This further supports the 
concept that integrin α11 is mainly expressed by a subpopulation 
of PDGFRβ+ CAFs in human BC. Next, we analyzed the associa-
tion between this α11/PDGFRβ–positive CAF subset and patient 
outcome. A positive correlation between the double α11/PDGFRβ 
positivity and high proliferation rate (percentage Ki67) was detect-
poorly modulated during PyMT tumor progression and not related 
to integrin α11 expression (Supplemental Figure 1, E and F).
To determine whether tumor-resident CAFs or other host inte-
grin α11+ cells are responsible for the observed phenotype, Itga11-
WT PyMT tumors were engrafted into Itga11-WT and -KO receiver 
mice (Supplemental Figure 2A). Similar tumor growth and mass 
(Supplemental Figure 2, A–C) were observed in both receiver 
mice. Histologically, transplanted tumors showed indistinguish-
able large and invasive tumor lobules (Supplemental Figure 2D) 
with strong stromal integrin α11/PDGFRβ expression (Supple-
mental Figure 2E). This demonstrates that integrin α11+ resident 
CAFs are sufficient to promote tumor progression in an environ-
ment proficient or deficient in Itga11.
ITGA11 expression is increased in human BCs. To deter-
mine whether integrin α11 expression is altered in human BC, a 
meta-analysis of publicly available gene expression data using 
the Oncomine database was performed. We compared ITGA11 
expression in 2415 BC versus 261 normal adjacent BC samples 
from 8 data sets. ITGA11 was found overexpressed in BC samples 
(gene median rank 2476.0, P = 1.92 × 10–10) in 7 of the 8 data sets 
included in the meta-analysis (Figure 4A and Supplemental Table 
1). Further analyses showed increased ITGA11 mRNA levels in 
BC samples including invasive ductal BC (Figure 4, B–D, G and 
H), invasive lobular BC (Figure 4B), invasive BC (Figure 4, B, E, 
and F), ductal BC in situ (Figure 4D), tubular BC (Figure 4C), and 
mixed lobular and ductal BC (Figure 4B) as compared with the 
corresponding normal breast tissues (P < 0.05). The high variance 
of ITGA11 expression observed in some tumor groups might result 
from interindividual and intratumoral heterogeneities.
Oncomine analysis of additional cancer data sets confirmed 
ITGA11 overexpression in several types of cancer relative to 
matched normal tissue, including lung, pancreas, colorectal, and 
gastric cancers (Supplemental Figure 3).
In addition, Kaplan-Meier analysis of BC patients stratified 
by ITGA11 mRNA levels showed that high ITGA11 mRNA levels 
(probe 23335_at) were correlated with lower overall (Figure 4I) and 
distant metastasis–free (Figure 4J) survival than were low ITGA11 
mRNA levels. Similar results were obtained with 2 other ITGA11 
probes (222899_at and 1554819_a_at). Collectively, these in sili-
co data suggest that increased ITGA11 mRNA levels observed in 
human BC associate with a worse prognosis.
ITGA11 expression correlates with a stromal gene signature in 
human BC. Given the stromal integrin α11 expression, we used 
Gene Expression Omnibus (GEO) microarray data sets to analyze 
the global gene expression in microdissected human BC spec-
imens: GSE14548, GSE33692, GSE41228 (36), and GSE68744 
(Figure 5, A–D). Elevated ITGA11 expression was found in the stro-
mal compartment as compared with the epithelia of both ductal 
carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC)/
invasive breast carcinoma (Figure 5, A–D). Furthermore, microar-
ray data sets (GSE8977, GSE9014, and GSE14548) comparing stro-
ma microdissected from normal breast and BC samples unveiled 
a significantly increased ITGA11 expression in cancerous stroma 
(Supplemental Figure 4, A–C).
Next, we searched for genes whose expression profile was 
best correlated (Pearson’s correlation coefficient > 0.5) to ITGA11 
mRNA levels in BC samples. Data mining was conducted in 3 BC 
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ed (Figure 6G). Furthermore, higher α11/PDGFRβ stromal densi-
ty was associated with high tumor grade, metastasis, and patient 
mortality (Figure 6, H–J). The analysis of the spatial distribution 
of α11+, PDGFRβ+, and double-positive cells (Figure 6K) revealed 
that α11/PDGFRβ double positivity was mostly associated with 
juxta-epithelial fibroblasts (high frequency at short distances).
Integrin α11–expressing CAFs promote in vitro tumor cell invasion 
in response to PDGF-BB. The in vivo and in silico studies revealed a 
strong association between integrin α11 and PDGFRβ in BC stro-
ma. We next performed Western blot analyses on several mouse 
and human primary cells and established cell lines: primary 
mouse PyMT CAFs (mCAFs) and cancer cells (PyMT), primary 
human breast CAFs (hCAFs), human blood (HUVEC) and lym-
phatic (HMVEC) endothelial cells, and MDA-MB-231, MCF-7, and 
SKBr3 human BC cells (Supplemental Figure 6A). Both mCAFs 
and hCAFs showed high integrin α11 expression levels, while other 
stromal and tumor cells had undetectable levels of this integrin. 
For functional investigations in vitro, 2 approaches were used: (a) 
CAFs were isolated from WT (mCAF WT) and KO (mCAF KO) 
PyMT late carcinomas; and (b) ITGA11 expression was downregu-
lated (knockdown [KD]) in WT CAFs issued from PyMT tumors or 
human BC CAFs through siRNA technology (mCAF/hCAF CTRL 
and KD). The overall efficiency of integrin knockdown was greater 
than 80% (Supplemental Figure 6B). Those different CAF popu-
lations were tested for their ability to remodel a collagen matrix 
and promote cell invasion (Figure 7, A–F, and Supplemental Fig-
ure 6, C–H). While WT CAFs contracted the collagen lattice to 
>80% of its original size, KO mCAFs achieved less than 60% of 
gel reduction within 96 hours (Supplemental Figure 6C). Similar-
ly, α11-silenced CAFs (mCAFs and hCAF1 KD) displayed impaired 
collagen contraction capacity (70% in CTRL mCAF/hCAF1 vs. 
40% in mCAF KD and 50% in hCAF1 KD) (Supplemental Fig-
ure 6, D and E). Next, we evaluated the impact of integrin α11 on 
CAF invasion in spheroids embedded in a 3D collagen matrix, a 
model implying ECM remodeling by proteases. Integrin α11 defi-
ciency impaired CAF invasion into the matrix under basal con-
ditions (Control) (Figure 7, A–C). Interestingly, when stimulated 
with PDGF-BB, the main ligand of PDGFRβ, mCAFs and hCAF1 
showed a strong increase in CAF invasion with a higher degree of 
response to PDGF-BB for α11+ CAFs compared with deficient ones 
(Figure 7, A–C). These data suggest that α11– CAFs are less sensi-
tive to PDGF-BB stimulation than their WT counterpart. These 
findings were confirmed with 3 other primary hCAFs (hCAF2–4) 
issued from hormone-positive or TNBC BC patients (Supplemen-
tal Figure 7, A–C).
We next evaluated the impact of integrin α11+ CAFs on tumor 
cell invasion upon PDGF-BB stimulation. To address the hetero-
geneity issues, CAFs were coculture with tumor cells with distinct 
molecular and invasive properties: mCAFs with PyMT tumor cells 
(low hormone sensitivity, more invasive) (Figure 7D) or hCAF1–4 
with MCF-7 (high hormone sensitivity, less invasive) and MDA-
MB-231 cells (hormone insensitivity, more invasive) (Figure 7, E 
and F, and Supplemental Figure 7, D–I). As previously seen in CAF 
homospheroids, α11+ CAFs in heterospheroids were more inva-
sive than α11-deficient ones (Supplemental Figure 6F). Tumor 
cell coculture with CAFs in heterospheroids resulted in increased 
tumor cell invasion as compared with that observed in homo-
spheroids. Moreover, integrin α11+ CAFs had a higher capacity to 
promote tumor cell invasion than α11-deficient CAFs (Figure 7, 
D–F, and Supplemental Figure 6G). Importantly, PDGF-BB treat-
ment strongly enhanced tumor cell invasion when tumor cells 
were cocultured with α11+ CAFs (Figure 7, D–F, and Supplemen-
tal Figure 6G), but not to α11-deficient CAFs. These data point to 
the incapacity of α11-deficient CAFs to promote tumor cell inva-
siveness via PDGF signaling. Notably, while CAFs were sensitive 
to PDGF-BB stimulation (Figure 7, A–C), tumor cell invasion was 
not affected by PDGF-BB treatment in homospheroids (Figure 7, 
D–F). The invasive promoting effects of CAFs were comparable 
for all tumor cell types (2 human and 1 murine) and CAFs used (4 
human and 1 murine) (Figure 7 and Supplemental Figure 7, D–I).
To investigate whether CAF-derived integrin α11 promotes 
tumor cell invasion by a direct cell-cell contact or through soluble 
factor production, we analyzed tumor cell invasion in homospher-
oids treated with conditioned medium derived from WT or KO 
CAFs prestimulated or not with PDGF-BB (Supplemental Figure 
6H). CAF-derived conditioned medium did not improve tumor 
cell invasion in the absence or the presence of PDGF-BB for both 
WT and KO CAFs. Thus, α11+ CAFs require cell-cell contacts or a 
juxtaposition to tumor cells to promote their invasion.
Integrin α11 promotes the activation of PDGFRβ and JNK down-
stream signaling. For mechanistic investigation, we evaluated the 
impact of integrin α11 on PDGFRβ activation and its downstream 
signaling. We first determined whether integrin α11 takes part in a 
molecular complex with PDGFRβ by coimmunoprecipitation (Fig-
ure 8A). While no α11/PDGFRβ complex was detected under basal 
conditions, a complex was formed within 5 minutes, peaked at 10 
minutes, and persisted until 60 minutes upon PDGF-BB stimula-
tion of WT CAFs. Given the key role of CrkII (herein named CRK) 
as a connector between tyrosine kinase receptors (RTKs), integ-
rins, and downstream effectors (39, 40), we searched for CRK in 
immunoprecipitates. In WT CAFs, a ligand-dependent recruit-
ment of CRK in the complex formed with PDGFRβ was detected 5 
minutes after stimulation and maintained concomitantly with the 
presence of integrin α11. In sharp contrast, the association of CRK 
in a molecular complex with PDGFRβ was reduced and transient 
(until 30 minutes) in KO CAFs, while the total amount of CRK 
protein was not modulated in comparison with the WT condition 
Figure 4. Integrin α11 expression is increased in human breast cancers. 
(A) Meta-analysis data of integrin α11 differential expression in BCs 
versus breast normal tissues. Oncomine microarray database was used to 
analyze ITGA11 mRNA expression, and meta-analysis was performed on 12 
analyses from 7 microarray data sets (2375 patients). Data are shown as 
median rank of ITGA11 expression through each data set analysis. P value 
for ITGA11 was determined using the median-ranked analysis of BC versus 
normal tissues. (B–H) Differential expressions of ITGA11 mRNA in the 7 
data sets included in the meta-analysis (Normal, normal adjacent breast 
tissue; IC, invasive breast carcinoma; IDC, invasive ductal breast carcino-
ma; IDC-L, mixed lobular and ductal breast carcinoma; IDC-T, invasive duc-
tal breast carcinoma–tubular type; ILC, invasive lobular breast carcinoma). 
Median and interquartile range (10th and 90th percentiles). Two-sided t 
test for 2-class differential expression analyses and Pearson’s correlation 
for multiclass analyses. FDR-corrected P values. (I and J) Kaplan-Meier 
plots showing the overall survival (I) and distant metastasis–free survival 
(J) for ITGA11 expression (probe: 23335_at). Log-rank P values calculated 
with the Kaplan-Meier plotter website.
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CRK interaction with PDGFRβ (Figure 8A), we investigated the 
phosphorylation of this adaptor molecule at the Y221 residue, a 
negative regulatory site of protein activity (41). Upon PDGF-BB 
stimulation, CRK was phosphorylated at Y221 in both WT and 
KO cells, confirming its recruitment by the receptor. Interesting-
ly, CRK inactivation through Y221 phosphorylation and intramo-
lecular folding was more pronounced in KO CAFs, suggesting a 
reduced CRK activation (Figure 9, A and B). To exclude the impli-
cation of PDGFRα, another partner of the CRK molecule, we inves-
tigated PDGFRα phosphorylation at the Y762 residue, the docking 
site for CRK (42). Upon PDGF-BB stimulation, no increase in Y762 
phosphorylation was seen, excluding PDGFRα implication in CRK 
activation in these cells (Supplemental Figure 8B).
The direct contribution of PDGFRβ in CRK, SRC, and JNK 
phosphorylation in WT cells is further supported by the phar-
macological blockade of their phosphorylation with imatinib, an 
inhibitor of PDGFRβ kinase activity (Figure 9C and Supplemen-
tal Figure 8C). We next investigated a target of PDGFRβ and JNK 
signaling, the proinvasive matricellular protein tenascin C (43, 
(Figure 8A). Immunofluorescence staining on CAFs revealed inte-
grin α11 clustering at focal adhesions in the absence or presence of 
PDGF-BB stimulation. Under basal conditions, PDGFRβ showed a 
diffuse distribution within WT and KO CAFs, while it colocalized 
within α11+ focal adhesions upon PDGF-BB stimulation. KO CAFs 
displayed diffuse and less organized PDGFRβ staining at the cell 
surface, even after PDGF-BB treatment (Figure 8B).
We next evaluated integrin α11 implication in PDGFRβ activa-
tion and downstream mediator phosphorylation (Figure 9, A and 
B). In WT CAFs, a robust PDGFRβ phosphorylation was detected 
after PDGF-BB stimulation, peaking from 5 minutes to 30 minutes 
and then gradually decreasing by 60 minutes (Figure 9, A and B). 
The highest difference in PDGFRβ phosphorylation between WT 
and KO CAFs was seen with Y771, while the classical Y751 residue 
was not affected by α11 deficiency (Figure 9A and Supplemental 
Figure 8A). Accordingly, no difference was detected in AKT, ERK, 
or PLCG1 phosphorylation between the two CAF genotypes (Sup-
plemental Figure 8A). A drastic reduction of JNK and SRC phos-
phorylation was detected in KO cells (Figure 9, A and B). Given 
Figure 5. Integrin α11 expression correlates with a stromal gene signature in human BC. (A–D) ITGA11 mRNA expression in microdissected stromal 
and epithelial compartments from ductal carcinoma in situ (DCIS) and invasive ductal (IDC)/invasive breast (IBC) carcinoma issued from GSE14548 (A), 
GSE41228 (B), GSE33692 (C), and GSE68744 (D) data sets. The log2-transformed ITGA11 expression values were exported from GEO2R and analyzed in 
GraphPad Prism. Significance was assessed by paired 2-tailed t test (normal distribution) and Wilcoxon matched-pairs signed-rank test (non-normal 
distribution). (E) Venn diagram depicting the overlap and number of genes associated with ITGA11 expression in BC across 3 genomic data sets (TCGA, 
METABRIC, and GenExMiner). (F) Reactome pathway-enriched analysis showing biological processes and pathways correlated with ITGA11-associated 
gene signature (top 20 significant pathways). Red dotted line, FDR-adjusted Q value = 0.05. (G) Targeted heat matrix showing correlation between ITGA11 
and 12 selected genes representing different tumor-associated cell populations. Data mining was performed using bc-GenExMiner 4.1. Color scale depicts 
Pearson’s correlation coefficients from –1 (dark blue, strong negative correlation) to +1 (dark red, strong positive correlation).
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Our study highlights that integrin α11 expression is mostly local-
ized in the stromal compartment of BC and provides evidence 
for a strong association between integrin α11 and PDGFRβ, both 
in clinical BC samples and in the preclinical PyMT mouse model. 
High PDGFRB expression has already been correlated with short-
er patient survival, and this molecule is proposed as a prognostic 
marker in many cancer types, including BC (23, 45, 46). Here, 
Kaplan-Meier analysis revealed that high ITGA11 expression 
is correlated with lower overall and metastasis-free survival of 
patients with BC. Additionally, integrin α11/PDGFRβ colocaliza-
tion was associated with a poor outcome, including high prolifer-
ation rate and histological grade, as well as increased metastasis 
and mortality. The integrin α11/PDGFRβ coexpression was dens-
er in invasive tumors and mostly confined to the juxta-epithelial 
fibroblasts. Because of technical limitation related to the lack of 
anti–integrin α11 antibody suitable on paraffin sections, our IHC 
study was restricted to frozen BC samples and is worth extending 
into larger cohorts. Our data are in line with a recent study show-
ing that PDGFRβ+ peritumoral fibroblasts constitute a poor prog-
nosis–associated fibroblast phenotype in DCIS (47). In agreement 
with the clinical data, Itga11 deficiency in mice drastically delayed 
PyMT tumor growth and reduced lung metastasis. Altogether, 
these findings indicate that integrin α11 exerts a tumor-promoting 
function and is mostly expressed by a subtype of PDGFRβ+ CAFs. 
However, we cannot exclude the possibility that integrin α11 dis-
plays additional protumoral features in a PDGFRβ-independent 
manner. Indeed, in both human and murine tumor samples, the 
α11/PDGFRβ–positive CAF subset represents around 70% of α11+ 
CAFs, with a remaining population of 30% of α11+PDGFRβ– CAFs. 
The moderate increase of the proinvasive activity of α11+ CAFs 
observed under basal conditions (without PDGF-BB) suggests that 
this integrin might also be involved in other protumoral effects.
The desmoplastic reaction represents a feature of disease 
malignancy and patient outcome in human BC (48). Our data 
mining revealed that ITGA11 expression strongly correlates with 
several fibroblastic markers and collagen molecules in human 
BC, further confirming an association of this integrin with CAFs 
and the desmoplastic reaction. Moreover, PDGF signaling was 
also linked to desmoplasia initiation in human BC (49), which 
additionally supports the synergistic crosstalk between integrin 
α11 and PDGFRβ. Interestingly, the ITGA11 upregulation that we 
initially found in human BC was confirmed in other desmoplastic 
cancers, including lung, pancreas, colorectal, and gastric cancers. 
It is worth mentioning that the second fibrillar collagen–binding 
α2β1 integrin (ITGA2) is downregulated in human BC and acts as a 
metastasis suppressor in a murine model (50). These data suggest 
opposite effects of the 2 fibrillar collagen–binding integrins (α2β1 
and α11β1) in BC.
Although PDGFRβ is a well-known marker of pericytes (19), 
the integrin α11+ cell subset is unlikely to be a pericyte subpopula-
tion, as integrin α11 positivity poorly correlates with αSMA or NG2. 
Additionally, the absence of an association between α11 and FSP1 
positivity suggests that α11+ cells are distinct from normal fibro-
blasts, as FSP1 was proposed as a marker of quiescent tissue fibro-
blasts (4) and is poorly expressed in late-stage PyMT tumors used 
in this study. The slight association between integrin α11 and FAP 
(22%) might reflect a partial overlap of FAP+, PDGFRβ+, and β1 
44). Under basal conditions, a high amount of tenascin C was pro-
duced by WT CAFs, which was strongly promoted by PDGF-BB 
(Figure 9, D and E). Conversely, KO CAFs produced a low amount 
of tenascin C (Figure 9D), even after PDGF-BB stimulation (Fig-
ure 9E). Pharmacological inhibition of PDGFRβ and JNK signal-
ing abolished PDGF-BB–induced tenascin C expression in WT 
CAFs, without affecting KO CAFs (Figure 9E). To further confirm 
the relevance of tenascin C, we analyzed human BC samples for a 
triple colocalization (Figure 10, A–C). Tenascin C, α11, and PDG-
FRβ were strongly coexpressed, particularly in IDC tumors when 
compared with normal associated tissues and DCIS (Figure 10A). 
Tenascin C expression was strongly correlated with the double 
receptor colocalization, particularly in IDC HER2 and TNBC sub-
types (Figure 10B). Furthermore, we measured the mean distance 
separating extracellular tenascin C–positive areas and α11/PDG-
FRβ–positive regions. An enrichment of tenascin C was detected 
at the proximity of α11/PDGFRβ–positive areas (Figure 10C).
Functional assays in the spheroid model were conducted to 
validate the implication of the PDGFRβ pathway in CAF invasion 
and CAF-induced tumor cell invasion. Pharmacological inhibi-
tion of PDGFRβ and JNK by imatinib and SP600125, respectively 
(Figure 11, A and C), blocked PDGF-BB–mediated CAF invasion. 
Importantly, tumor cell invasion in homospheroids was not affect-
ed by PDGFRβ or JNK inhibition (Figure 11, B and D). However, 
tumor cell invasion in heterospheroids with WT CAFs was com-
pletely restored to the control baseline by both PDGFRβ and JNK 
inhibition. Collectively, these findings demonstrate that integrin 
α11–modulated PDGFRβ/JNK signaling in CAFs is an important 
pathway to promote cancer cell invasiveness.
Discussion
Tumor cells are not self-supporting entities, and their metastatic 
abilities are affected by stromal cells, including a heterogeneous 
population of CAFs. In this study, by using human BC sam-
ples and transgenic mice with spontaneous onset of mammary 
tumors, we identified an integrin α11/PDGFRβ–positive CAF 
subset displaying tumor-promoting features that is associated 
with a poor clinical outcome. The link between stromal integrin 
α11 and PDGFRβ has been established at (a) the transcriptional 
level in human BC samples by data mining, (b) the histological 
level in human and murine BC by IHC, (c) the cellular level by 
immunostaining on CAFs, (d) the molecular level by coimmuno-
precipitation assay, and (e) the functional level in in vitro assays. 
Mechanistically, we uncover a role for integrin α11 in regulating 
PDGFRβ signaling and its downstream JNK activation, which 
leads to increased expression of one of its targets, tenascin C, 
a proinvasive matricellular protein, strongly coexpressed with 
integrin α11 and PDGFRβ in clinical samples. We provide clear 
evidence that integrin α11/PDGFRβ molecular crosstalk exploits 
JNK signaling to endow CAFs with protumorigenic abilities in 
sustaining the invasiveness of BC cells.
The originality of the present work is to investigate integrin 
α11, a fibrillar collagen–binding β1 integrin, mainly expressed by 
fibroblastic cells. Previous studies already reported that this inte-
grin is expressed by mesenchymal cell types in wound healing and 
lung cancer (29, 32, 33). Whether or not integrin α11 expression is 
restricted to a specific CAF subset has not yet been documented. 
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with PDGFRβ likely favors JNK downstream signaling, rather than 
classical ERK or AKT pathways. The involvement of additional 
molecular partners/pathways cannot be excluded.
PDGFRβ or JNK pharmacological inhibition impaired not 
only CAF invasion but, most importantly, the invasiveness of 
cancer cells in mixed spheroids. Notably, cancer cells them-
selves are not sensitive to PDGF-BB stimulation, further high-
lighting the contribution of integrin α11 in CAF/cancer cell 
crosstalk. An important finding is that α11+ CAFs issued either 
from mice or from human patients (4 different subpopulations) 
were all able to promote tumor cell invasion, independently of 
intrinsic tumor cell properties. Therefore, α11+ CAFs display a 
proinvasive activity on tumor cells, and the extent of this effect 
might be tumor cell–dependent.
The tumor-promoting capacities of CAFs have been wide-
ly described as being related to their secretome and their ability 
to remodel the ECM (4). Our study demonstrates that integrin 
α11+ CAFs promote cancer cell invasion via cell-cell contact or in 
a proximal manner. This process could imply the local produc-
tion of growth factors, migratory modulators, or matrix mole-
cules and/or involve matrix remodeling (54). Integrins have been 
shown to mediate CAF-induced invasion of cancer cells, by gen-
erating tracks within the matrix through the combined action of 
force- and protease- mediated matrix remodeling (14). Our study 
provides evidence that the crosstalk between integrin α11 and 
PDGFRβ and subsequent JNK activation contribute to the acquisi-
tion of CAF protumorigenic abilities. The integrin α11/PDGFRβ/
JNK molecular axis results in changes in ECM composition with 
increased deposition of at least one proinvasive matricellular pro-
tein (tenascin C). Previous studies have clearly documented that 
fibroblast-derived tenascin C is a key matricellular protein that 
promotes tumor cell invasion (14, 55, 56). Notably, its increased 
expression in tumors is associated with disease progression and 
metastasis (57). In line with our data, both PDGF and JNK signal-
ing pathways have been reported to regulate tenascin C expres-
sion (43, 44). Moreover, our study reveals a strong association 
between α11/PDGFRβ–positive CAFs and tenascin C expression, 
particularly in IDC and more aggressive BC molecular subtypes. 
Although tenascin C regulation contributes to the proinvasive 
effects exerted by CAFs on tumor cells, we cannot exclude the 
putative involvement of proteases and other proinvasive ECM 
molecules in this model.
Collectively, our work sheds a new light on the role played by 
integrin α11 in BC stroma. This integrin associates mainly with 
PDGFRβ in a CAF subset displaying tumor-promoting and pro-
metastatic potential. We identify the integrin α11/PDGFRβ/JNK 
axis as an important mediator of CAF-promoted tumor invasive-
ness. Pharmacological approaches targeting such a molecular 
partnership may have strong implications in cancer treatment and 
prediction of patient response to RTK treatments.
Methods
Generation of Itga11-deficient MMTV-PyMT mouse model. Itga11-knock-
out mice (Itga11tm1Dgul) (35) were backcrossed into an FVB/N back-
ground (Harlan Laboratories) for 6 generations, and then crossed with 
MMTV-PyMT FVB/N transgenic mice expressing polyoma middle 
T antigen oncogene under mouse mammary tumor virus promoter 
integrin+ CAF subsets as previously reported (12). Given the mul-
tiple putative cellular sources of CAFs, it is possible that host α11+ 
cells other than resident fibroblasts contribute to tumor growth. 
This possibility was excluded by transplantation of WT tumors 
into KO mice leading to tumor growth similar to that in WT mice. 
This clearly demonstrates that tumor-resident α11+ cells are suffi-
cient for the observed protumoral effects.
A key finding of our study is the ligand-dependent interaction 
of PDGFRβ with integrin α11 assessed by coimmunoprecipitation 
and immunofluorescence studies. Importantly, the 2 proteins 
colocalized at focal adhesions. Along with the classical integrin/
ECM signaling, integrin/RTK crosstalk is already documented 
for several RTKs, including EGFR, IGFR, FGFR, PDGFR, and 
Met receptors (26, 51). Integrins can promote phosphorylation 
of RTKs and/or amplify their intracellular signaling. In this con-
text, clustering of cell surface β1 integrins has been reported to 
induce PDGFRβ phosphorylation (25). In our system, upon ligand- 
induced interaction of PDGFRβ with integrin α11, we observed an 
increase of receptor phosphorylation, suggesting a collaborative 
signaling between this RTK and integrin α11 (26). When consid-
ering downstream mediators of PDGFRβ signaling, we observed 
a modulation of CRK, SRC, and JNK phosphorylation. CRK and 
SRC implication in integrin signaling is widely described (52, 53). 
PDGFRβ is known to bind and phosphorylate CRK adaptor mol-
ecules (42). Accordingly, our data demonstrate that α11-PDGFRβ 
interaction is associated with CRK recruitment assessed by coim-
munoprecipitation assay, as well as SRC and JNK activation (see 
graphical abstract). The absence of integrin α11 does not prevent 
the formation of CRK/PDGFRβ complex but increases CRK phos-
phorylation at Y221, the negative regulator site of its activity. Phar-
macological inhibition of PDGFRβ by imatinib altered the phos-
phorylation of CRK, SRC, and JNK. Thus, integrin α11 interaction 
Figure 6. Integrin α11/PDGFRβ density is associated with a poor clinical 
outcome in BC. (A) Representative confocal pictures of immunofluores-
cence costaining of integrin α11 (red) and PDGFRβ (green) in human breast 
samples: tumor tissues and normal associated tissues from patients 
with ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) 
of luminal A and B, HER2, or triple-negative (TNBC) breast cancers. Scale 
bar: 50 μm. Nuclei stained with DAPI (blue). (B–D) Quantification of 
density of integrin α11 (B), PDGFRβ (C), and their colocalization (D) on BC 
samples. Data are presented as percentage of stained area normalized 
to total tumor area. n = 68 patients (n = 11 DCIS, n = 14 IDC luminal A, n = 
17 IDC luminal B, n = 11 IDC HER2, n = 15 IDC TNBC). One-way ANOVA with 
Dunnett’s (B) and Kruskal-Wallis with Dunn’s multiple-comparisons tests 
(C and D). (E and F) Overall percentage of integrin α11/PDGFRβ–positive 
cells normalized to total integrin α11+ (E) or PDGFRβ+ cells (F). Minimum 
6 stromal fields per tumor, n = 68 patients. Kruskal-Wallis with Dunn’s 
multiple-comparisons test. (G) Correlation of integrin α11/PDGFRβ 
colocalization density from D with percentage of Ki67 in human BC. n = 
68 patients. Pearson correlation analysis. (H–J) Association of integrin 
α11/PDGFRβ colocalization density with BC grade (H), metastasis (I), and 
survival (J) outcomes. n = 68 patients. One-way ANOVA with Tukey’s mul-
tiple-comparisons (J) and Mann-Whitney (H and I) tests. (K) Quantification 
of spatial enrichment of integrin α11 (red), PDGFRβ (green), and colocal-
ization (yellow) areas versus tumor areas in human BC samples. Data are 
presented as frequency of stained pixels as a function of the distance to 
tumor areas. n = 56 stromal fields. Significance between the distribution 
curves was determined by Kolmogorov-Smirnov test within the distance 
range of 0–100 μm.
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Figure 7. Integrin α11–expressing CAFs promote in vitro tumor cell invasion in response to PDGF-BB. (A–C) Representative spheroid pictures 
of red-tracked WT and KO mCAFs (A), CTRL and KD mCAFs (B), and CTRL and KD hCAF1 (C) after 20 hours of invasion in a 3D collagen matrix 
stimulated with PDGF-BB (10 ng/mL). Scale bars: 200 μm. Zoomed pictures (×2) are in lower right panels. Cell invasion quantification is present-
ed in bottom panels. Data are expressed as maximal distance of invasion from the spheroid border (Lmax). n = 5–20 (A); n = 5–8 (B); n = 6–15 (C). 
Representative of 3 independent experiments. One-way ANOVA with Tukey’s multiple-comparisons test. (D–F) Representative homo- and hetero-
spheroid pictures of green-tracked PyMT tumor cells and red-tracked WT and KO mCAFs (D) and green-tracked MCF-7 and MDA-MB-231 tumor cells 
and red-tracked CTRL and KD hCAF1 (E and F) after 20 hours of seeding in collagen. Scale bars: 200 μm. Zoomed pictures (×2) in lower right panels. 
Bottom panels correspond to tumor cell invasion quantification (Lmax). n = 5–18 (D); n = 8–19 (E); n = 5–13 (F). Representative of 3 independent 
experiments. One-way ANOVA with Tukey’s multiple-comparisons test.
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and KO groups. For the “KO late” group, Itga11-deficient mice 
were left longer than 14 weeks (maximum until week 18), until 
they reached the same tumor volume as WT mice at 14 weeks.
For transplantation experiments, matched WT PyMT 
tumors (11 weeks old, 2-mm fragments) were engrafted into fat 
pads of FVB/N Itga11-WT or -KO mice (aged 10–12 weeks), and 
tumor volumes were estimated twice a week.
Cell isolation from mouse and human samples. Mouse CAFs 
(mCAFs) and PyMT tumor cells (PyMT) were isolated from 
PyMT mice as previously described (59). Late carcinoma 
tumor samples were surgically removed at week 14. Samples 
were cut into small pieces and enzymatically digested with a 
collagenase solution for 45 minutes at 37°C (collagenase type 
IA, Clostridium histolyticum, Sigma- Aldrich, Belgium). After 
filtration and centrifugation of cell suspension, the pellet was 
washed, resuspended, and cultured in medium defined below. 
Cells were plated for 30 minutes to let fibroblasts adhere. The 
supernatant containing tumor cells was then removed and plat-
ed in a separate flask. All PyMT tumor cells were positive for 
cytokeratin. Primary cultured CAFs were used at early passag-
es (until passage 5 and for no longer than 14 days of culture). 
CAFs were positive for vimentin and negative for cytokeratin. 
Human CAFs (hCAFs), isolated in a similar way, were derived 
from women undergoing a mammectomy with the following 
tumor characteristics: hCAF1 (99% estrogen receptor–posi-
tive, 25% progesterone receptor–positive and HER2-negative), 
hCAF2 (95% estrogen- and progesterone receptor–positive and 
HER2-negative), hCAF3 and hCAF4 (triple-negative). Primary 
cells were isolated by preparation of a single-cell suspension 
from tumor fragments (1–3 mm3) followed by culture plate 
adherent passaging. They were positive for vimentin (100%) 
and negative for cytokeratin. Primary hCAF2–4 were used until 
passage 4. The hCAF1 were immortalized after infection with 
a pBABE retroviral vector expressing the hTERT open reading 
frame (hTERT hCAF1) and used until passage 8.
Cell culture and siRNA transfection. CAFs, PyMT tumor cells, and 
human BC cell lines (MCF-7, MDA-MB-231, and SKBr3, obtained 
from ATCC) were cultured in DMEM (Gibco, Thermo Fisher Scien-
tific) supplemented with 10% FBS, l-glutamine (2 mM), penicillin 
(100 U/mL), and streptomycin (100 μg/mL) at 37°C and humidified 
in a 5% CO2 atmosphere until they reached 90%–100% confluence. 
Human primary blood (HUVEC) and lymphatic (HMVEC-D) endo-
thelial cells were cultured in EGM2 and EGM2-MV medium (Lonza, 
Verviers, Belgium), respectively. All cells were mycoplasma-free. 
[Tg(MMTV-PyVT)634Mul] for 6 generations (34). All animals were 
kept within the accredited Mouse Facility and Transgenics GIGA plat-
form of the University of Liège (Liège, Belgium) in specific pathogen–
free conditions. Genotyping was performed by PCR of tail genomic 
DNA as previously described (58). Primer sequences for Itga11 and 
PyMT are presented in Supplemental Table 4. Tumor growth was 
assessed by measurement of the tumor volume (V = length × width2 
× 0.4) twice a week and the tumor mass at sacrifice. Tumor measure-
ment started at week 5 after birth and continued until week 14 for WT 
Figure 8. Integrin α11 interacts with PDGFRβ in a ligand-depen-
dent manner. (A) Western blot kinetics of PDGFRβ coimmuno-
precipitation with integrin α11 and CRK in response to PDGF-BB 
(10 ng/mL) after 0, 5, 10, 30, and 60 minutes of treatment in WT 
and KO mCAFs. Total extracts are shown in the corresponding 
lower panels. (B) Confocal immunofluorescence colocalization of 
integrin α11 (red) and PDGFRβ (green) before (Control) and after 
treatment with PDGF-BB (10 ng/mL) for 10 minutes in WT and KO 
mCAFs. Nuclei counterstained with DAPI. Scale bars: 40 μm.
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Figure 9. Integrin α11 regulates PDGFRβ downstream activation and promotes tenascin C expression in CAFs. (A) Western blot of protein phosphoryla-
tion for PDGFRβ (Y771), CRK (Y221), SRC (Y416), and JNK (T183/S185) after 0, 5, 10, 30, and 60 minutes of PDGF-BB (10 ng/mL) stimulation in WT and KO 
mCAFs. (B) Quantified kinetics of PDGFRβ, CRK, SRC, and JNK protein phosphorylation from A. Data are presented as normalized ratio between phosphor-
ylated and total proteins. n = 7 (Y771-PDGFRβ); n = 4 (Y221-CRK); n = 3 (Y416-SRC); n = 4 (T183/Y185-JNK) of independent experiments. Two-way ANOVA 
with Holm-Šidák multiple-comparisons test. (C) Western blot of protein phosphorylation for PDGFRβ (Y771), CRK (Y221), SRC (Y416), and JNK (T183/S185) 
after PDGF-BB (10 ng/mL) stimulation in WT mCAFs pretreated or not with imatinib (5 μM) for 1.5 hours. (D) Confocal immunofluorescence staining of 
integrin α11 (red) and tenascin C (TNC) (green) in WT and KO mCAFs. Nuclei stained with DAPI. Scale bar: 40 μm. (E) Western blot analysis of tenascin C 
expression before or after PDGF-BB (10 ng/mL) stimulation in WT and KO mCAFs pretreated or not with imatinib (5 μM) or SP600125 (5 μM) for 20 hours. 
**P < 0.01; ***P < 0.001.
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light microscope observation. For desmoplasia analysis, a Van Gieson 
staining was performed by incubation of slides with Weigert’s iron 
hematoxylin solution followed by Van Gieson staining (Sigma-Aldrich, 
Belgium). Slides were scanned using the NanoZoomer 2.0-HT system 
(Hamamatsu, Belgium), and automatic quantification was performed 
with the image analysis toolbox of MATLAB 8.3 software (MathWorks 
Inc.). Desmoplasia was expressed as collagen density normalized to 
total tumor area. For metastasis quantification, 6 lung sections, each 
taken at a distance of between 6 μm and 10 μm, were analyzed for 
each mouse. Metastatic index was calculated by division of the tumor 
lung area by the total lung area.
Immunofluorescence studies. For colocalization studies on mouse 
samples, cryosections embedded in OCT (6 μm thickness) were fixed 
in acetone at –20°C for 10 minutes, followed by rehydration and block-
ing in Protein Block, Serum-Free Solution (Dako, Agilent) for 10 min-
utes. Primary and secondary antibodies (references and dilutions in 
Supplemental Table 5) were incubated sequentially in Antibody Dilu-
ent with Background Reducing Components (Dako, Agilent). Slides 
were mounted in DAPI Fluoromount-G (SouthernBiotech) and ana-
lyzed within 48 hours after staining. For integrin α11 and PDGFRβ 
colocalization on human samples, cryosections of human carcinoma 
and the associated normal breast tissues were analyzed for the fol-
lowing groups: ductal carcinoma in situ (DCIS) and invasive ductal 
carcinomas (IDCs) of luminal A and B, HER2, and TNBC cancers (68 
patients). For detection of integrin α11 on human samples, the anti-hu-
man Mab203E1H5 antibody was produced (72) (antibody deposited 
under Patent Application EP18155716, European Patent Office). All 
samples were analyzed by confocal Olympus Fluoview 1000 micros-
copy in Kalman filter mode with a ×20-magnification objective. For 
image analysis and quantification, protein expression hotspots were 
identified within tumor sections (at least 6 stromal fields per sample), 
and integrin α11, PDGFRβ, and colocalization densities were quanti-
fied by specifically designed algorithm in MATLAB 8.3 software. The 
proximity analysis was performed by identification of the Euclidean 
distance from each pixel belonging to integrin α11+, PDGFRβ+, and 
colocalized positive areas to tumor nodules. Pictures lacking defined 
tumor areas were excluded. For triple colocalization, the proximity of 
tenascin C to the colocalized integrin α11/PDGFRβ areas was calcu-
lated as described above. For immunofluorescence studies on CAFs, 
low-confluence cells (20%–30%) were fixed in methanol/acetone 
mixture (80/20) at –20°C for 10 minutes, followed by rehydration and 
blocking in Innovex Background Buster (Innovex Biosciences) for 10 
minutes. Cells were incubated with primary and secondary antibod-
ies as described above. Samples were analyzed by confocal Olympus 
Fluoview 1000 microscopy in Kalman filter mode with a ×60-magni-
fication oil immersion objective.
Collagen contraction assay. For each replicate, 2 × 105 cells were 
suspended in 700 μL of native collagen solution (2 mg/mL) buff-
ered at pH = 7.5 (rat tail Collagen I, Corning) and seeded in a 12-well 
plate pretreated with 2% BSA solution. After collagen polymeriza-
tion at 37°C, gels were detached carefully from the well border, and 
medium supplemented with 5% FBS was added. Collagen lattice 
contraction was monitored for 96 hours by taking of pictures dai-
ly with an LAS-4000 image analyzer (Fujifilm, Belgium). Gel area 
was measured by ImageJ (NIH) software, and the percentage of gel 
reduction was calculated by subtraction of the gel area for each day 
from the gel area at time 0 hours.
All human cell lines described above were authenticated before use 
(Leibniz Institute DSMZ). For ITGA11/Itga11 downregulation, cells 
at 60%–70% confluence were transfected for 48 hours before exper-
iments with INTERFERin siRNA transfection reagent (Polyplus) 
and Mouse or Human SMARTpool: ON-TARGETplus Itga11 siR-
NA (Dharmacon) (20 nM) in DMEM supplemented with 10% FBS. 
ON-TARGETplus Non-targeting Control Pool (Dharmacon) was used 
as negative transfection control. ITGA11/Itga11 downregulation was 
confirmed after 48–72 hours by Western blot. For Western blot and 
coimmunoprecipitation experiments, cells were used at 90%–100% 
confluence after 3 days of seeding. For immunofluorescence confo-
cal detection, low-confluence cells (20%–30%) were used 20 hours 
after seeding. For PDGF-BB stimulation, high-confluence cells were 
serum-starved for 2 hours, followed by PDGF-BB stimulation (R&D 
Systems) (10 ng/mL). For imatinib experiments, high-confluence 
cells were serum-starved for 2 hours and pretreated with imatinib (LC 
Laboratories) (5 μM) for 1.5 hours followed by PDGF-BB stimulation.
Bioinformatics analysis. Meta-analysis of global gene expression 
data in the Oncomine database (60) (Compendia Bioscience, Ann 
Arbor, Michigan, USA) was performed using primary filters for “breast 
cancer” and “cancer vs. normal analysis,” sample filter for “clinical 
specimens,” and data type filter for “mRNA” data sets (8 data sets rep-
resenting 2415 patients). Patients of all ages, sexes, disease stages, or 
treatments were included. Data were acquired in an unbiased manner 
by compiling of all the Oncomine studies with significantly altered 
ITGA11 expression at the threshold settings (P = 0.05, fold change = 
1.5, and gene rank = all) (60). Significant studies in which at least 1 ana-
lyzed group was composed of 3 patients or fewer were excluded. All 
data are reported as log2 median-centered intensity in the Oncomine 
database. The data sets were exported from Oncomine and analyzed 
in GraphPad Prism version 7 software.
The gene expression profiles of GSE8977 (61), GSE9014 (62), 
GSE14548 (63), GSE33692 (64), GSE41228 (36), and GSE68744 (65) 
were obtained from the NCBI Gene Expression Omnibus (GEO) data-
base (66), and data were recalculated using the GEO2R analytical tool 
(67). The log2-transformed expression values of ITGA11 were export-
ed from GEO2R and analyzed in GraphPad Prism. Identification of 
genes whose expression profiles were best correlated with ITGA11 
mRNA levels was performed by interrogation of gene expression data 
sets contained at cBioPortal and Breast Cancer Gene-Expression Min-
er (bc-GenExMiner). bc-GenExMiner contains 36 data sets including 
5861 BC patients (68). cBioPortal was used to explore the TCGA breast 
(69) and METABRIC (70) cohorts. For each of these 3 patient cohorts 
(referred to as TCGA, METABRIC, and GenExMiner), genes with Pear-
son’s correlation coefficients greater than 0.5 were selected and clas-
sified as being ITGA11-coexpressed genes. The intersections of coex-
pressed genes from the 3 cohorts were analyzed using the Venny 2.1 
online tool. Kaplan-Meier curves were generated with the Kaplan-Mei-
er plotter website (http://kmplot.com/analysis/), using a database of 
public microarray data sets (71). Automatic cutoff scores were selected 
during queries; overall survival (OS) and distant metastasis–free surviv-
al (DMFS) were selected. Log-rank P values were computed as previ-
ously described (71). Integrative coexpression network was analyzed in 
the TCSBN database as previously described (38).
Histological analysis. Mouse tumor and lung samples were forma-
lin-fixed (4%) and paraffin-embedded. Sections of 6 μm thickness 
were counterstained with H&E and mounted with Eukitt medium for 
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Figure 10. Integrin α11/PDGFRβ density 
is associated with tenascin C enrich-
ment in human BC. (A) Representative 
immunofluorescence pictures of integrin 
α11 (red), PDGFRβ (green), and tenascin C 
(TNC) (pink) costaining in human breast 
samples: normal associated breast tis-
sue, ductal carcinoma in situ (DCIS), and 
invasive ductal carcinomas (IDC) from 
luminal A and B, HER2, or TNBC patients. 
Scale bar: 50 μm. Nuclei stained with 
DAPI. (B) Correlation of integrin α11/
PDGFRβ colocalization density with TNC 
expression on human BC samples from 
A. Data are presented as percentage of 
density (stained area/total tumor area). 
n = 18 patients (n = 6 DCIS, n = 3 IDC 
luminal A, n = 3 IDC luminal B, n = 3 IDC 
HER2, n = 3 IDC TNBC). Pearson correla-
tion analysis. (C) Spatial enrichment of 
TNC versus integrin α11/PDGFRβ colo-
calized areas in BC samples from A and 
B. Data are presented as mean of the 
Euclidean distance of TNC to colocalized 
areas. n = 18 patients. Kruskal-Wallis 
with Dunn’s multiple-comparisons test.
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tions. Protein complexes were resuspended in Dynabeads Protein G 
solution (50 μL; Thermo Fisher Scientific) and incubated for 8 hours 
at 4°C. Protein-bead complexes were collected from a magnet system, 
washed, and resuspended in Lysis Buffer and heated for 5 minutes 
at 95°C. Samples were next analyzed by Western blot. Total protein 
extracts, CAF KO, IgG, and input samples were used as immunopre-
cipitation controls.
Statistics. Unless otherwise stated, statistical analysis was per-
formed with SigmaPlot and GraphPad Prism software, and results are 
expressed as mean ± SEM. For 2-group comparison, 2-tailed unpaired 
t test or Mann-Whitney test was performed. For multiple-group com-
parison, 1-way ANOVA or Kruskal-Wallis tests were performed with 
the multiple-comparison post hoc correction as indicated. Equal-
ity-of-variance test between groups and Shapiro-Wilk normality 
test were performed, and statistical tests were chosen accordingly. 
Graphs show exact P values or asterisks P less than 0.05 was consid-
ered significant.
Study approval. All animal experiments were conducted at the 
GIGA Animal Facility of the University of Liège (ULiège; Belgium) in 
accordance with the Federation of European Laboratory Animal Sci-
ence Associations and the local ethical committee at ULiège. Cryosec-
tions of human BC samples and related normal associated tissues (n 
= 68 including 11 DCIS, 14 IDC luminal A, 17 IDC luminal B, 11 IDC 
HER2, and 15 IDC TNBC) were provided by the Biobank of the Uni-
versity Hospital of Liège for a retrospective study in accordance with 
current legislation and recommendations of the Ethical Committee of 
the University Hospital of Liège.
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Spheroid invasion assay. For fluorescence cell tracking, CAFs and 
tumor cells were incubated for 30 minutes in serum-free medium with 
CellTracker Green CMFDA or Orange CMRA (Invitrogen, Thermo 
Fisher Scientific). Spheroids were prepared by seeding of 500 CAFs or 
1000 tumor cells (homospheroids) or a mixture of both (heterospher-
oids) in 200 μL of DMEM supplemented with 10% FBS and contain-
ing 20% of carboxymethylcellulose 4000 cP (Sigma-Aldrich). Cells 
were seeded in round-bottom nonadherent 96-well plates (CELL-
STAR, Greiner Bio-One) for 24 hours for spheroid formation. The 
following day, single spheroids were collected from wells, centrifuged, 
and suspended in 500 μL/well of native collagen solution (2 mg/mL; 
rat tail Collagen I, Corning) at pH 7.5 and seeded in collagen-precoated 
12-well plates (15 spheroids per well; 2 wells per condition). After col-
lagen polymerization, 500 μL of DMEM supplemented with 2% FBS 
was carefully added. For PDGF-BB stimulation, spheroids were treat-
ed with recombinant human PDGF-BB (10 ng/mL; R&D Systems). In 
some assays, imatinib (LC Laboratories) and SP600125 (Sigma-Al-
drich) were added (5 μM). Spheroids were analyzed after 20 hours 
of culture, and image acquisition was performed by epifluorescence 
Nikon Eclipse Ti microscope (×10-magnification objective). Image 
analysis was performed as previously described (73). Cell invasion was 
automatically quantified by specifically designed algorithm in MAT-
LAB 8.3 software. Data were expressed as the maximal distance of cell 
invasion from the spheroid border.
RNA extraction and quantitative reverse transcriptase PCR analysis. 
Total tumor RNA was extracted using the RNeasy Mini Kit (Qiagen 
GmbH). RNA was quantified and purity checked with the ND-1000 
NanoDrop spectrophotometer (NanoDrop Technologies). Quantita-
tive reverse transcriptase PCR was performed on reverse-transcribed 
RNA (First Strand cDNA Synthesis kit, Roche) with LightCycler480 
Probes Master kit (Roche) and the Universal Probe Library system 
(Roche) using specific primers (Eurogentec). Data were normalized 
to mouse TBP. Primer nucleotide sequences are indicated in Supple-
mental Table 4.
Western blot and coimmunoprecipitation analysis. For protein 
extraction, frozen tumor samples or fresh cells were suspended in 
Lysis Buffer (Cell Signaling Technology) supplemented with Complete 
protease and PhoStop phosphatase inhibitor cocktails (Roche). Tumor 
samples were homogenized with the MagnaLyser system (Roche), 
while cell samples were scraped on ice. After centrifugation at 14,000 
g for 10 minutes at 4°C, proteins were quantified with the DC protein 
assay kit (Bio-Rad Laboratories). Tumor (100 μg) or cell extracts (20 
μg) were separated by SDS-PAGE under reducing conditions. PVDF 
membranes (PerkinElmer Life Sciences) were incubated for 1 hour in 
5% nonfat dry milk or BSA PBS solution, followed by overnight incu-
bation with primary antibodies. Antibodies and dilutions are indicat-
ed in Supplemental Table 5. Immunocomplexes were detected with an 
ECL-Plus enhanced chemiluminescence system and visualized with 
an image analyzer (LAS-4000; Fujifilm, Belgium). Band densities 
were quantified with Quantity-One software (Bio-Rad Laboratories). 
For loading control, membranes were incubated with HSC-70 anti-
body. For phosphorylation experiments, membranes were stripped 
in Restore Western Blot Stripping Buffer (Thermo Fisher Scientific), 
reblocked, and reincubated with antibodies for total protein detection. 
For coimmunoprecipitation analysis, 700 μg of protein extracts were 
immunoprecipitated overnight with PDGFRβ antibody (clone 2B3, 
Cell Signaling Technology) according to the manufacturer’s instruc-
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 6 2 6 jci.org   Volume 129   Number 11   November 2019
Figure 11. Pharmacological inhibition of PDGFRβ or JNK reverses PDGF-BB–induced invasiveness of integrin α11–WT CAFs and of cancer cells in hetero-
spheroids. (A and C) Representative homospheroid pictures of red-tracked WT and KO mCAFs after 20 hours of invasion in collagen in response to PDGF-
BB (10 ng/mL) and upon treatment with 5 μM of imatinib (PDGFRβ inhibition) (A) or SP600125 (JNK inhibition) (C). Scale bars: 200 μm. Quantification of 
cell invasion is presented in the corresponding graphs. Data are expressed as maximal distance of invasion from the spheroid border (Lmax). n = 8–17 (A); 
n = 5–11 (C). Kruskal-Wallis with Dunn’s multiple-comparisons (A) and 1-way ANOVA with Tukey’s multiple-comparisons (C) tests. (B and D) Representa-
tive homo- and heterospheroid pictures of green-tracked PyMT tumor cells and red-tracked WT and KO mCAFs after 20 hours of invasion in response to 
PDGF-BB (10 ng/mL) and upon treatment with 5 μM of imatinib (B) or SP600125 (D). Scale bars: 200 μm. Quantification of tumor cell invasion (Lmax) is 
presented in the corresponding graphs. n = 12–21 (B); n = 9–22 (D). Kruskal-Wallis with Dunn’s multiple-comparisons test.
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